RenovoRX Device Saves Grandfather From Cancer
Hernando Salcedo first noticed the swelling in his stomach in May 2025.
The 83-year-old grandfather had lived a healthy life in Miami, spending his days gardening and playing with his grandchildren.
But the strange bloating signaled a silent and deadly invader.
Doctors at a local hospital ran tests and delivered a devastating diagnosis: Stage III pancreatic cancer.
The news hit the family like a physical blow.
Pancreatic cancer is notorious for its low survival rates.
Official statistics show the five-year survival rate hovers around just 15 percent.
For Stage III patients, the odds are often even grimmer because the tumor has grown into major blood vessels or nearby organs.
Salcedo faced a difficult road ahead.
The standard treatment involves aggressive chemotherapy.
Doctors often use a combination of drugs to try to shrink the tumor.
But the biology of pancreatic cancer makes it incredibly resistant to these systemic treatments.
The tumor acts like a fortress, blocking drugs from entering.
Salcedo began chemotherapy immediately.
The treatments were grueling.
They left him exhausted and weak.
Despite the effort, the initial results were not promising.
The tumor remained stubbornly present.
Time was running out.
The family braced for the worst.
They looked for alternatives.
They needed a miracle.
That search led them to the Miami Cancer Institute.
There, a team of specialists was testing a new approach.
They were not just fighting the cancer with drugs.
They were changing how the drugs were delivered.
This shift in strategy would change everything for Salcedo.
Miami Cancer Institute Panel Chose a Different Path
The Miami Cancer Institute operates differently than standard hospitals.
They use a multidisciplinary approach to treat complex cases.
A panel of experts reviews each patient's file.
This group includes surgeons, radiologists, and medical oncologists.
They meet to discuss the best path forward.
When Salcedo's case came before the board, they saw a candidate for innovation.
His cancer was locally advanced.
It had not spread to distant organs like the lungs or liver.
This made him a potential candidate for a clinical trial.
The institute was participating in a study for a device called RenovoRX.
The panel recommended Salcedo for the trial.
It was a decision based on specific medical criteria.
The goal was to bypass the limitations of traditional chemotherapy.
Traditional IV chemo sends toxic drugs throughout the entire body.
It attacks healthy cells along with cancer cells.
This causes the terrible side effects patients fear.
Hair loss, nausea, and immune system suppression are common.
The RenovoRX device offers a targeted solution.
It is a catheter-based system designed for intra-arterial chemotherapy.
Doctors thread a tiny catheter into the arteries feeding the tumor.
This allows them to deliver the chemotherapy directly to the cancer site.
The medical team explained the procedure to Salcedo.
They told him it could concentrate the drug where it was needed most.
It could spare the rest of his body from the harshest effects.
Salcedo agreed to the trial.
He put his trust in the technology and the team.
The procedure took place in a specialized interventional radiology suite.
It required precision and skill.
The team navigated the complex blood vessels near the pancreas.
Once the catheter was in position, they began the infusion.
The chemotherapy flowed directly into the tumor's blood supply.
This marked a turning point in his battle.
RenovoRX Device Attacks Dense Tissue Directly
Pancreatic tumors are unique in their structure.
They are surrounded by a thick, fibrous tissue called a stroma.
This stroma acts like a scar tissue wall.
It is incredibly dense.
It creates high pressure inside the tumor.
This pressure prevents chemotherapy from penetrating effectively when given through an IV.
The drugs essentially bounce off the outer wall.
The RenovoRX device solves this physics problem.
By using pressure-driven delivery, the device forces the chemotherapy into the tumor.
It overcomes the resistance of the stroma.
Think of it like watering a plant with a fire hose instead of a spray bottle.
The water reaches the roots directly.
This method achieves a much higher concentration of the drug in the tumor tissue.
Studies suggest this concentration can be many times higher than with IV methods.
This saturation helps kill the cancer cells more effectively.
At the same time, the drug levels in the rest of the body stay lower.
This reduces the systemic toxicity.
Patients often report fewer side effects.
They feel stronger during treatment.
They can maintain a better quality of life.
For Salcedo, the difference was noticeable.
He did not experience the severe nausea he had with IV chemo.
He had more energy.
The device specifically targets the arteries supplying the pancreas.
It isolates the treatment zone.
This precision is a major leap forward in oncology.
It represents a shift from systemic poisoning to targeted engineering.
Doctors believe this approach could be applied to other difficult cancers.
Liver cancer and certain breast tumors might also benefit.
The success of the device relies on the skill of the radiology team.
They must map the blood supply accurately.
They must avoid spillage into other organs.
The team at Miami Cancer Institute has mastered this technique.
Their expertise was a crucial factor in Salcedo's outcome.
Ben Sasse's Diagnosis Highlights a National Crisis
While Salcedo fought his battle in Miami, the nation watched another high-profile fight.
Ben Sasse, the former United States Senator from Nebraska, revealed his own diagnosis.
In a candid interview, Sasse shared that he had Stage IV pancreatic cancer.
His story brought renewed attention to the disease.
Sasse described the severity of his condition.
He told reporters, "My torso is chock full of tumors."
His statement underscored the aggressive nature of this cancer.
It highlighted that the disease does not discriminate.
It affects the young and old, the powerful and the powerless.
Sasse was 52 at the time of his announcement.
This is younger than the typical patient.
His case shocked many.
It served as a stark reminder of the gaps in medical science.
Pancreatic cancer is currently the third leading cause of cancer death in the United States.
It is projected to become the second leading cause soon.
These statistics are alarming.
They reflect the difficulty of early detection.
There are no reliable screening tests for the general public.
By the time symptoms appear, like jaundice or back pain, the disease is often advanced.
Researchers are working hard to change this.
Some are exploring blood tests to find tumor markers early.
Others are investigating the role of probiotics and the gut microbiome.
Recent studies suggest engineered bacteria might boost the immune system's attack on tumors.
Vaccines are also in development.
However, these treatments are years away from widespread use.
Patients today need solutions now.
This urgency makes the RenovoRX trial so important.
It offers a tangible benefit using existing drugs in a better way.
It bridges the gap between current standards and future cures.
The contrast between Sasse's struggle and Salcedo's success illustrates the variability of the disease.
It also shows the importance of access to cutting-edge trials.
Every patient deserves the chance to beat the odds.
Salcedo Beats Odds as Trial Shows Promise
The results of the clinical trial for Hernando Salcedo were remarkable.
Over the months following the procedure, his scans began to change.
The medical team monitored his progress closely.
They used CT scans and MRI images to measure the tumor.
They watched as the mass began to shrink.
The dense tissue that defined the cancer started to break down.
By July 2026, more than a year after his diagnosis, Salcedo was defying expectations.
He had survived a disease that claims most patients within months.
His quality of life had returned.
He was back in his garden.
He was cooking for his family again.
The doctors declared a significant response to the therapy.
The tumor was no longer a threat to his vital organs.
It had shrunk enough to be manageable.
In some cases, this shrinkage makes surgery possible.
While Salcedo's specific surgical status remains private, the control of the disease was a victory in itself.
The success of the trial at Miami Cancer Institute is adding to a growing body of data.
Researchers are compiling results from patients across the country.
The data suggests that intra-arterial delivery improves survival rates.
It extends the time patients live without the cancer growing.
This is known as progression-free survival.
For Salcedo, every extra month is a gift.
He celebrated his 84th birthday with a large family party.
He spoke about the importance of hope.
He emphasized the need to seek out specialized care.
His story is a beacon for others facing the same diagnosis.
It proves that clinical trials are not just experiments.
They are lifelines.
The medical team continues to follow his case.
They are gathering data to understand the long-term benefits.
So far, the results are encouraging.
The RenovoRX device has shown it can be safe and effective.
It has turned a terminal diagnosis into a chronic condition for some patients.
New Targeted Therapies Reshape Cancer War
The story of Hernando Salcedo is more than a single medical success.
It signals a shift in the war on cancer.
For decades, the primary weapons were blunt instruments.
Surgery, radiation, and chemotherapy were the standard trio.
They saved lives, but they often came at a high cost.
The future of oncology lies in precision.